EUVIMEDEUVIMED entdecken
Crossref

Thyroxine overuse and clinical indices guiding successful treatment withdrawal

Sarantis Livadas, Nicholas Angelopoulos, Anastasios Kollias, Rodis D Paparodis, Ioannis Androulakis, Panagiotis Anagnostis, Anastasios Boniakos, Dimitrios Askitis, Djuro Macut, Juan C Jaume, Leonidas Duntas

Journal of Endocrinological Investigation · 03.02.2025 · 48 (5) · 1139-1147

DOI: 10.1007/s40618-025-02543-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 03.02.2025. Verfasst von Sarantis Livadas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Unit, Athens Medical Center, Athens, Greece. sarantislivadas@gmail.com. Hauptthemen laut MEDLINE: Thyroxine, Hypothyroidism, Withholding Treatment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Levothyroxine (LT4) is commonly prescribed, but there is evidence strongly suggesting that a significant proportion of these patients are on treatment without solid evidence of hypothyroidism. Small trials on treatment discontinuation, did not detect any predictors of success. Therefore, we conducted this study in an attempt to identify predicting factors for successful LT4 withdrawal. METHODS: In 802 consecutive patients (83% females, mean age 48 ± 16 years) on LT4 treatment for 8.8 ± 7.3 years without a solid diagnosis of hypothyroidism, therapy was abruptly discontinued. A total of 387 persons were followed up for up to 4 months (group A) and 415 individuals who were euthyroid at 4 months post LT4 discontinuation, were followed up for up to 60 months (group B). Recurrent hypothyroidism was defined if thyrotropin (TSH) level exceeded 4.5mIU/L. RESULTS: Among the entire cohort, 182 patients (23%) became hypothyroid, 40% of group A and 7% of group B (p < 0.001). The Τhyroid treatment Discrimination Index (T4RxDI), the product of TSH levels multiplied by the daily LT4 dose divided by BMI, was calculated. In group A, successful LT4 withdrawal was strongly indicated by a T4RxDI value < 2.78 (72% sensitivity, 66% specificity), while in group B, the corresponding value was 3.75 (100% sensitivity, 48% specificity). CONCLUSIONS: Our findings reveal considerable overuse of LT4 and propose a T4RxDI product of < 3 as a valuable predictive factor of recurrent hypothyroidism, justifying a treatment discontinuation trial. If hypothyroidism does not resume within 4 months, the risk of developing long-term hypothyroidism is likely to be minimal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyroxineHypothyroidismWithholding TreatmentHumansFemaleMiddle AgedMaleAdultFollow-Up StudiesThyrotropinPrognosisThyroid Function TestsAged

Stichwörter der Autor:innen

DiscontinuationHypothyroidismTSHThyroxine

Substanzen

ThyroxineThyrotropin

Autor:innen und Institutionen

  • Endocrine Unit, Athens Medical Center, Athens, Greece. sarantislivadas@gmail.com.
  • Hellenic Endocrine Network, Athens, Greece. sarantislivadas@gmail.com.
  • Hellenic Endocrine Network, Athens, Greece.
  • Third Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.
  • Department of Medicine, Jr. VA Hospital, Edward Hines, Loyola University Chicago, Hines, IL, 60141, USA.
  • First Department of Obstetrics and Gynecology, Unit of Reproductive Endocrinology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Zitieren

APA

Livadas, S., Angelopoulos, N., Kollias, A., Paparodis, R. D., Androulakis, I., Anagnostis, P., Boniakos, A., Askitis, D., Macut, D., Jaume, J. C., & Duntas, L. (2025). Thyroxine overuse and clinical indices guiding successful treatment withdrawal. Journal of Endocrinological Investigation, 48(5), 1139-1147. https://doi.org/10.1007/s40618-025-02543-2

Vancouver

Livadas S, Angelopoulos N, Kollias A, Paparodis RD, Androulakis I, Anagnostis P, et al. Thyroxine overuse and clinical indices guiding successful treatment withdrawal. Journal of Endocrinological Investigation. 2025;48(5):1139-1147. doi:10.1007/s40618-025-02543-2

BibTeX
@article{Livadas2025,
  author = {Livadas, Sarantis and Angelopoulos, Nicholas and Kollias, Anastasios and Paparodis, Rodis D and Androulakis, Ioannis and Anagnostis, Panagiotis and Boniakos, Anastasios and Askitis, Dimitrios and Macut, Djuro and Jaume, Juan C and Duntas, Leonidas},
  title = {Thyroxine overuse and clinical indices guiding successful treatment withdrawal},
  journal = {Journal of Endocrinological Investigation},
  year = {2025},
  volume = {48},
  number = {5},
  pages = {1139--1147},
  doi = {10.1007/s40618-025-02543-2}
}
Kostenlos starten →